EMEA-000117-PIP01-07-M07
Key facts
Invented name |
Yervoy
|
Active substance |
Ipilimumab
|
Therapeutic area |
Oncology
|
Decision number |
P/0085/2015
|
PIP number |
EMEA-000117-PIP01-07-M07
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except melanoma, nervous system, haematopoietic and lymphoid tissue)
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-000117-PIP01-07-M07
|
Compliance opinion date |
11/12/2015
|
Compliance outcome |
positive
|